Clofarabine, cyclophosphamide, and etoposide (CLOVE) in adult patients with relapsed/refractory acute T-cell lymphoblastic leukemia: single-center experience

Basit Öğe Kaydı
dc.authoridÇelik, Serhat/0000-0002-1052-9800
dc.authoridKeklik, Muzaffer/0000-0002-6426-5249
dc.authoridGüven, Zeynep Tuğba/0000-0003-1600-9731
dc.contributor.authorGüven, Zeynep Tuğba
dc.contributor.authorTubay, Saziye Esra
dc.contributor.authorÇelik, Serhat
dc.contributor.authorKeklik, Muzaffer
dc.contributor.authorÜnal, Ali
dc.date.accessioned2025-01-21T16:33:43Z
dc.date.available2025-01-21T16:33:43Z
dc.date.issued2023
dc.departmentKırıkkale Üniversitesi
dc.description.abstractPurpose: Clofarabine is a second-generation purine analog that inhibits DNA synthesis. It is used as an effective new agent in relapsed refractory acute leukemia. We aimed to report our single center experience about CLOVE protocol as a clofarabine-based regimen in patients with relapsed or refractory T-cell acute lymphoblastic leukemia.Materials and Methods: Thirteen patients with relapsed or resistant T-cell acute lymphoblastic leukemia were included in this study. Patients were administered clofarabine (40 mg/m2/day), etoposide (100 mg/m2/day), and cyclophosphamide (440 mg/m2/day) (5 days chemotherapy). The patients' data were reviewed retrospectively, the demographic and clinical characteristics of patients were recorded.Results: The patients' median age was 47, and 77% (n:10) of them were male. The median number of chemotherapy regimens they received before clofarabine was 3. Of the patients, 54% (n=7) presented with relapse, and 46% (n=6) with refractory disease. Hematological side effects were observed in all patients during treatment, and 4 (31%) patients were complicated by febrile neutropenia. Other side effects were hepatotoxicity 39%, skin reaction 2%, nausea 54%, and mucositis 31%. Three (23%) patients were unresponsive to treatment. A response was obtained in 10 (77%) patients. Allogeneic stem cell transplantation was performed in 4 of 5 patients with complete response. The median follow-up time after CLOVE was 2.3 (0.69- 26.02) months. The median estimated survival time was 21.04 & PLUSMN; 3.88 (95%CI: 13.43-28.64) months. Overall survival was 85.7% at three months and 57.1% at one year. Three patients were alive at the end of our study.Conclusion: The combination of clofarabine, etoposide, and cyclophosphamide (CLOVE) appears to be successful in achieving a response in relapsing or resistant acute leukemia. However, more effective regimens are still needed.
dc.identifier.doi10.17826/cumj.1274325
dc.identifier.endpage540
dc.identifier.issn2602-3032
dc.identifier.issn2602-3040
dc.identifier.issue2
dc.identifier.startpage535
dc.identifier.trdizinid1197744
dc.identifier.urihttps://doi.org/10.17826/cumj.1274325
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay1197744
dc.identifier.urihttps://hdl.handle.net/20.500.12587/23843
dc.identifier.volume48
dc.identifier.wosWOS:001038321300025
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.publisherCukurova Univ, Fac Medicine
dc.relation.ispartofCukurova Medical Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241229
dc.subjectClofarabine; relapsed; resistant leukemia; T-cell acute lymphoblastic leukemia
dc.titleClofarabine, cyclophosphamide, and etoposide (CLOVE) in adult patients with relapsed/refractory acute T-cell lymphoblastic leukemia: single-center experience
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Tam Metin/Full Text
Boyut:
234.44 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu